A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Advanced Solid Tumors
DRUG: HRS-4642
Stage 1: (IB Period):DLTs, Within 28 days of the first dose|Stage 1: (IB Period): adverse events (AEs), Within 28 days of the first dos,About 1 year|Phase II: (Phase II):investigator-assessed ORR, Assessed every 6 weeks,About 1 year
Stage 1: (IB Period):Investigator-assessed objective response rate (ORR), Assessed every 6 weeks,About 1 year|Phase II: (Phase II):DCR, Assessed every 6 weeks,About 1 year|Phase II: (Phase II):DoR, Assessed every 6 weeks,About 1 year|Phase II: (Phase II):OS, Assessed every 6 weeks+ About 1 year|Phase II: (Phase II):PFS, Assessed every 6 weeks,About 1 year|Phase II: (Phase II):OS, Assessed approximately once every 1 month,About 1 year|Phase II: (Phase II):Incidence and severity of AEs, Assessed approximately once every 1 month,About 1 year
To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).